scholarly journals Administration of Protein‐Conjugate Pneumococcal Vaccine to Patients Who Have Invasive Disease after Splenectomy Despite Their Having Received 23‐Valent Pneumococcal Polysaccharide Vaccine

2005 ◽  
Vol 191 (7) ◽  
pp. 1063-1067 ◽  
Author(s):  
Daniel M. Musher ◽  
Heather Ceasar ◽  
Erna M. Kojic ◽  
Benjamin L. Musher ◽  
Joseph C. Gathe, Jr. ◽  
...  
Keyword(s):  
Pneumococcal Vaccine ◽  
Invasive Disease ◽  
Polysaccharide Vaccine ◽  
Pneumococcal Polysaccharide Vaccine ◽  
Protein Conjugate ◽  
Conjugate Pneumococcal Vaccine

scholarly journals In-Hospital Pneumococcal Polysaccharide Vaccination Is Associated With Detection of Pneumococcal Vaccine Serotypes in Adults Hospitalized for Community-Acquired Pneumonia

2015 ◽  
Vol 2 (4) ◽  
Author(s):  
Carlos G. Grijalva ◽  
Richard G. Wunderink ◽  
Yuwei Zhu ◽  
Derek J. Williams ◽  
Robert Balk ◽  
...  
Keyword(s):  
Pneumococcal Vaccine ◽  
Community Acquired Pneumonia ◽  
Polysaccharide Vaccine ◽  
Urine Collection ◽  
Pneumococcal Polysaccharide Vaccine ◽  
Test Results ◽  
Pneumococcal Serotypes ◽  
False Positive Test ◽  
Pneumococcal Antigen ◽  
Urine Specimens

Abstract During an etiology study of adults hospitalized for pneumonia, in which urine specimens were examined for serotype-specific pneumococcal antigen detection, we observed that some patients received 23-valent pneumococcal polysaccharide vaccine before urine collection. Some urine samples became positive for specific vaccine pneumococcal serotypes shortly after vaccination, suggesting false-positive test results.

scholarly journals Conjugate Pneumococcal Vaccine in HIV‐Infected Ugandans and the Effect of Past Receipt of Polysaccharide Vaccine

2005 ◽  
Vol 192 (10) ◽  
pp. 1801-1805 ◽  
Author(s):  
George Miiro ◽  
Helena Kayhty ◽  
Christine Watera ◽  
Helen Tolmie ◽  
James A. G. Whitworth ◽  
...  
Keyword(s):  
Pneumococcal Vaccine ◽  
Polysaccharide Vaccine ◽  
Conjugate Pneumococcal Vaccine

Pneumococcal vaccine in adults reduces the risk of infections caused by Streptococcus pneumoniae

2016 ◽  
Vol 94 (1) ◽  
pp. 61-66
Author(s):  
Yulia G. Belocerkovskaja ◽  
A. G. Romanovskih ◽  
E. A. Styrt
Keyword(s):  
Streptococcus Pneumoniae ◽  
Conjugate Vaccine ◽  
Pneumococcal Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Risk Group ◽  
Severe Disease ◽  
Polysaccharide Vaccine ◽  
Pneumococcal Vaccines ◽  
Pneumococcal Polysaccharide Vaccine ◽  
Pneumococcal Infections

Streptococcus pneumoniae is a major cause of severe disease worldwide, particularly in the risk population. Two pneumococcal vaccines are currently available for specific prevention of pneumococcal infections among adults in Russia: a 23-valent pneumococcal polysaccharide vaccine (PPSV23) and a 13-valent pneumococcal conjugate vaccine (PCV13). The article describes modern views on the effectiveness and safety of two pneumococcal vaccines in adults with underlying medical conditions and adults aged ≥65 years and provides current recommendations for routine use of PPSV23 and PCV13 among persons included in the risk group.

Sign in / Sign up

Export Citation Format

Share Document